Welcome to this week’s FiercePharmaAsia report, which includes stories about Celgene’s $1.4 billion PD-1 deal with Beigene, Fosun’s headache cause | Celgene is buying Chinese firm Beigene’s PD-1 inhibitor BGB-A317, Fosun’s stock slides as rumors about its chairman emerge again, Neopharma is making a series of expansions in Japan and Abu Dhabi, and more.
